CureC9 and BrainXell Partner on ALS and FTD Research
CureC9 and BrainXell have partnered to advance research into amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The collaboration aims to enhance access to high-quality resources for patient-driven innovation.
CureC9, a patient-driven initiative focused on accelerating treatments for C9orf72-associated ALS and FTD, has announced a partnership with BrainXell. The collaboration is intended to expand access to high-quality research resources, thereby furthering the understanding and treatment of ALS and FTD. BrainXell brings expertise in the field of neurological disorders. CureC9 emphasizes a patient-centric approach, leveraging the experiences and needs of patients within the research process. This partnership is expected to foster patient-driven innovation in the development of therapies for these conditions. Combining BrainXell's technological capabilities with CureC9's patient-focused strategy is anticipated to establish a robust foundation for future research endeavors. The initiative aims to yield significant advancements for researchers and patients affected by ALS and FTD.